Taysha Gene Therapies Inc (TSHA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2021 | 12-2020 | 09-2020 | 06-2020 | 03-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -32,024 | -60,011 | -41,693 | -26,651 | -5,431 |
| Depreciation Amortization | 32 | 9 | 3 | N/A | N/A |
| Accounts payable and accrued liabilities | 1,872 | 1,961 | 5,403 | 1,237 | N/A |
| Other Working Capital | 863 | -111 | 6,438 | 2,456 | 912 |
| Other Operating Activity | 7,222 | 27,423 | 18,968 | 18,793 | 2,820 |
| Operating Cash Flow | $-22,035 | $-30,729 | $-10,881 | $-4,165 | $-1,699 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -534 | -82 | -31 | N/A | N/A |
| Purchase Sale Intangibles | N/A | -9,000 | -3,000 | -3,000 | N/A |
| Other Investing Activity | 0 | -9,000 | -3,000 | -3,000 | 0 |
| Investing Cash Flow | $-534 | $-9,082 | $-3,031 | $-3,000 | $N/A |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | 1,673 | 1,673 | 1,673 | 1,673 |
| Debt Repayment | N/A | -1,673 | -1,673 | -1,645 | -1,646 |
| Common Stock Issued | N/A | 165,854 | 167,162 | N/A | N/A |
| Other Financing Activity | 0 | 125,210 | 125,384 | 18,337 | 18,000 |
| Financing Cash Flow | $N/A | $291,064 | $292,546 | $18,365 | $18,027 |
| Beginning Cash Position | 251,253 | N/A | N/A | N/A | N/A |
| End Cash Position | 228,684 | 251,253 | 278,634 | 11,200 | 16,328 |
| Net Cash Flow | $-22,569 | $251,253 | $278,634 | $11,200 | $16,328 |
| Free Cash Flow | |||||
| Operating Cash Flow | -22,035 | -30,729 | -10,881 | -4,165 | -1,699 |
| Capital Expenditure | -534 | -82 | -31 | N/A | N/A |
| Free Cash Flow | -22,569 | -30,811 | -10,912 | -4,165 | -1,699 |